The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Glufosfamide in Treating Patients With Recurrent Glioblastoma Multiforme
Official Title: Open Label Phase II Study On Glufosfamide Administered As A 60 Minute Infusion Every 3 Weeks In Recurrent Glioblastoma Multiforme
Study ID: NCT00014300
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of glufosfamide in treating patients who have recurrent glioblastoma multiforme.
Detailed Description: OBJECTIVES: I. Determine the activity of glufosfamide, in terms of objective response rate and/or progression-free survival at 6 months, in patients with recurrent glioblastoma multiforme. II. Determine the duration of objective response in patients treated with this regimen. III. Determine the toxic effects and pharmacokinetic profile of this regimen in these patients. OUTLINE: This is a multicenter study. Patients receive glufosfamide IV over 60 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients with stable disease receive treatment for a minimum of 6 months or until progression. Patients with an objective complete response receive a maximum of 2 additional courses of treatment after confirmation of response. Patients are followed every 6 weeks until progression. PROJECTED ACCRUAL: A total of 28 patients will be accrued for this study.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Kaiser Franz Josef Hospital, Vienna (Wien), , Austria
Centre Jean Perrin, Clermont-Ferrand, , France
Centre de Lute Contre le Cancer,Georges-Francois Leclerc, Dijon, , France
Centre Leon Berard, Lyon, , France
CRLCC Nantes - Atlantique, Nantes-Saint Herblain, , France
Centre Antoine Lacassagne, Nice, , France
CHU Pitie-Salpetriere, Paris, , France
Centre Eugene Marquis, Rennes, , France
Institut Gustave Roussy, Villejuif, , France
University of Ioannina, Ioannina, , Greece
Schneider Children's Medical Center of Israel, Petah-Tikva, , Israel
Azienda Ospedaliera di Padova, Padova (Padua), , Italy
Istituti Fisioterapici Ospitalieri - Roma, Rome, , Italy
Rotterdam Cancer Institute, Rotterdam, , Netherlands
Academisch Ziekenhuis Utrecht, Utrecht, , Netherlands
Instituto Portugues de Oncologia de Francisco Gentil, Lisbon, , Portugal
Centre Hospitalier Universitaire Vaudois, Lausanne, , Switzerland
Kantonsspital - St. Gallen, St. Gallen, , Switzerland
Name: Martin J. van Den Bent, MD
Affiliation: Daniel Den Hoed Cancer Center at Erasmus Medical Center
Role: STUDY_CHAIR